Anti-human interleukin-20 antibodies

US8287861B2 · kind B2 · utility

Assignee

• Novo Nordisk A/S · DK

Inventors

• Jesper Pass · Ringe, DK
• Søren Østergaard · Copenhagen, DK
• Jes Thorn Clausen

Key dates

• Filing date: Jun 30, 2009
• Grant date: Oct 16, 2012
• Expiry date: Jun 30, 2029

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/76
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Anti-human IL20 monoclonal antibodies that can reduce IL20 mediated activation of both IL20R1/IL20R2 and IL22R1/IL20R2 receptor complexes in one or more species, including humans, are described, as well as antigen-binding molecules such as, e.g., antigen-binding antibody fragments, antibody derivatives, and multi-specific molecules designed or derived from such antibodies, and methods or producing such antibodies or other antigen-binding molecules. Such antibodies or other antigen-binding molecules can be used for treating various diseases and disorders, including autoimmune or inflammatory diseases or disorders.